Clinical Trial

Assessing Pharmacokinetics and Pharmacodynamics of Daily Enteric-coated Aspirin in Patients With StablE Diabetes

Study acronym: APPEASED

Active, Not Recruiting Early Phase 1

Summary

This phase 1 study will include patients suffering from type 2 diabetes mellitus and will study their response to enteric coated aspirin at a dose of 80 mg per day for a 7-day period. The aims are to determine the feasibility of a phase 2 larger scale trial, and to characterize the prevalence of incomplete platelet inhibition after exposure to EC aspirin at doses of 80 mg once daily. Platelet function will be assessed at baseline and a day 7.

Protocol Amendment History 5 amendments

This ClinicalTrials.gov record has been amended 5 times since 2021-10-23; most recent amendment 2025-12-01.

Status change: Recruiting → Active, Not Recruiting 2025-12-01

Trial Details

NCT Number	NCT05105919
Lead Sponsor	Montreal Heart Institute Collaborators: Institut de Recherches Cliniques de Montreal
Conditions	Diabetes Mellitus, Type 2
Enrollment	50 participants
Start Date	2021-08-26
Primary Completion	2024-04-01 (estimated)
Study Completion	2025-12-01 (estimated)
Updated on ClinicalTrials.gov	2025-12-08